Frontier Medicines

This year, our management team will be attending the Jefferies Global Healthcare Conference in London. If you’re interested in reconnecting or learning more about Frontier, please reach out. See you in London!  

Yesterday, we announced we’re presenting preclinical data from three of our pipeline programs at this year’s AACR-NCI-EORTC International Conference on Molecular Targets.    The data we are presenting at the Triple Meeting this year is a testament to our ability to execute across challenging targets and to the power of the FrontierTM Platform.    Our CSO, Kevin Webster, comments on the data.  https://bit.ly/49cqad6

Today, we announced we are presenting preclinical data from three of our pipeline programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets, taking place in Boston, MA., from October 22 to 26.    All three programs demonstrated efficacy in a single-agent setting and in combination with other therapies in preclinical models.    For more on this preclinical data from across our pipeline, read more: https://bit.ly/49cqad6

ICYMI, Bree Foster, PhD, of Drug Discovery News, recently covered our publication in Structure, demonstrating that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation (TPD). The article covers how we made this discovery, what it means for #targetedproteindegradation, and “highlights the enormous, largely untapped potential of the human E3 ligase family in drug discovery.” https://bit.ly/4oxkaAf

ICYMI, we recently announced our third clinical development candidate, FMC-242. Our CEO, Chris Varma, comments on FMC-242, and the efficiency of the FrontierTM Platform and its ability to unlock the proteome to develop differentiated medicines against traditionally undruggable targets.    Read more: https://bit.ly/3WB0Wxv

At this year’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the Frontier team will present three posters highlighting preclinical data across our precision medicine pipeline:    -FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasib resistant PDX models  -FMC-220, a highly potent and selective covalent activator of p53 Y220C, is broadly active in p53 Y220C containing PDX models across cancer indications  -FMC-242, a highly potent and selective covalent inhibitor of the PI3Ka-RAS interaction that demonstrates improved efficacy and tolerability as monotherapy and in combination with targeted therapies in preclinical models    We look forward to seeing many of you in Boston! 

Kevin Webster, our chief scientific officer, comments on our newest drug candidate, FMC-242.    This approach, breaking the interaction between the PI3Ka and RAS proteins, could benefit patients with activating mutations or amplification of receptor tyrosine kinases, RAS and PI3Ka. It has potential both as a monotherapy, and when used in combination to overcome resistance to common targeted therapies.  https://bit.ly/3WB0Wxv   #PrecisionMedicine 

Today, we announced our latest development candidate, FMC-242, a covalent allosteric inhibitor that breaks the interaction between the PI3Ka and RAS proteins. This mechanism of action inhibits PI3Kα/AKT effector signaling in tumors while minimizing the toxicities commonly associated with the broader class of inhibitors. We believe it has potential as a monotherapy and could be a foundational treatment when used in combination with other medicines, including those in our own pipeline.    #PrecisionOncology #PrecisionMedicine    Read more: https://bit.ly/3WB0Wxv

On Friday, we announced a publication in Structure demonstrating DCAF2 is a novel E3 ligase that can be used to degrade proteins. This is a compelling example of how our platform enables us to see more deeply into the proteome and develop novel ways to hit difficult targets.    Our team discovered DCAF2 can covalently and selectively bind to small molecules and cause the degradation of other proteins, opening up a novel target site for TPD and a new avenue for the development of therapeutic bifunctional degraders and molecular glues that leverage DCAF2.    Our own @Weiru Wang, lead author, comments. https://bit.ly/42Tlvcf